BioPharma Dive November 11, 2024
Jonathan Gardner

Aucatzyl, developed by the U.K. biotech Autolus, may cause fewer side effects than Tecartus in people with a type of leukemia.

Dive Brief:

  • The Food and Drug Administration on Friday approved a new cell therapy for a type of leukemia. Called Aucatzyl, the CAR-T was developed by U.K.-based Autolus Therapeutics to treat people with B-cell precursor acute lymphoblastic leukemia whose disease has progressed following treatment with chemotherapy and other medicines.
  • Aucatzyl will compete with Gilead Sciences’ Tecartus, which won approval in the same condition in 2021. The Gilead cell therapy had sales of $305 million in the first nine months of 2024, but Autolus executives claim its drug could outperform Tecartus because it was designed to cause fewer side...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments
FDA’s Recent Guidance on Accelerated Approval and Implications for Rare Diseases
This Bill Could Make It Legal for AI to Prescribe Medicine

Share This Article